Metabolomics and Cardiovascular Biomarker Discovery

被引:176
作者
Rhee, Eugene P. [3 ,4 ]
Gerszten, Robert E. [1 ,2 ,4 ]
机构
[1] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA
[4] Broad Inst, Cambridge, MA USA
关键词
CORONARY-ARTERY-DISEASE; HEART-DISEASE; RISK; REVEALS; MARKERS; METABOLISM; EVENTS; PLASMA; BLOOD; TECHNOLOGIES;
D O I
10.1373/clinchem.2011.169573
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Metabolomics, the systematic analysis of low molecular weight biochemical compounds in a biological specimen, has been increasingly applied to biomarker discovery. CONTENT: Because no single analytical method can accommodate the chemical diversity of the entire metabolome, various methods such as nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) have been employed, with the latter coupled to an array of separation techniques including gas and liquid chromatography. Whereas NMR can provide structural information and absolute quantification for select metabolites without the use of exogenous standards, MS tends to have much higher analytical sensitivity, enabling broader surveys of the metabolome. Both NMR and MS can be used to characterize metabolite data either in a targeted manner or in a nontargeted, pattern-recognition manner. In addition to technical considerations, careful sample selection and study design are important to minimize potential confounding influences on the metabolome, including diet, medications, and comorbitidies. To this end, metabolite profiling has been applied to human biomarker discovery in small-scale interventions, in which individuals are extremely well phenotyped and able to serve as their own biological controls, as well as in larger epidemiological cohorts. Understanding how metabolites relate to each other and to established risk markers for diseases such as diabetes and renal failure will be important in evaluating the potential value of these metabolites as clinically useful biomarkers. SUMMARY: Applied to both experimental and epidemiological study designs, metabolite profiling has begun to highlight the breadth metabolic disturbances that accompany human disease. Experimental work in model systems and integration with other functional genomic approaches will be required to establish a causal link between select biomarkers and disease pathogenesis. (C) 2011 American Association for Clinical Chemistry
引用
收藏
页码:139 / 147
页数:9
相关论文
共 36 条
[1]   Metabolomics Applied to Diabetes Research Moving From Information to Knowledge [J].
Bain, James R. ;
Stevens, Robert D. ;
Wenner, Brett R. ;
Ilkayeva, Olga ;
Muoio, Deborah M. ;
Newgard, Christopher B. .
DIABETES, 2009, 58 (11) :2429-2443
[2]  
Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802
[3]   Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate [J].
Dunn, Warwick B. ;
Broadhurst, David I. ;
Deepak, Sasalu M. ;
Buch, Mamta H. ;
McDowell, Garry ;
Spasic, Irena ;
Ellis, David I. ;
Brooks, Nicholas ;
Kell, Douglas B. ;
Neyses, Ludwig .
METABOLOMICS, 2007, 3 (04) :413-426
[4]   Measuring the metabolome: current analytical technologies [J].
Dunn, WB ;
Bailey, NJC ;
Johnson, HE .
ANALYST, 2005, 130 (05) :606-625
[5]   Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease [J].
Elliott, Paul ;
Chambers, John C. ;
Zhang, Weihua ;
Clarke, Robert ;
Hopewell, Jemma C. ;
Peden, John F. ;
Erdmann, Jeanette ;
Braund, Peter ;
Engert, James C. ;
Bennett, Derrick ;
Coin, Lachlan ;
Ashby, Deborah ;
Tzoulaki, Ioanna ;
Brown, Ian J. ;
Mt-Isa, Shahrul ;
McCarthy, Mark I. ;
Peltonen, Leena ;
Freimer, Nelson B. ;
Farrall, Martin ;
Ruokonen, Aimo ;
Hamsten, Anders ;
Lim, Noha ;
Froguel, Philippe ;
Waterworth, Dawn M. ;
Vollenweider, Peter ;
Waeber, Gerard ;
Jarvelin, Marjo-Riitta ;
Mooser, Vincent ;
Scott, James ;
Hall, Alistair S. ;
Schunkert, Heribert ;
Anand, Sonia S. ;
Collins, Rory ;
Samani, Nilesh J. ;
Watkins, Hugh ;
Kooner, Jaspal S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (01) :37-48
[6]   The search for new cardiovascular biomarkers [J].
Gerszten, Robert E. ;
Wang, Thomas J. .
NATURE, 2008, 451 (7181) :949-952
[7]   Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum [J].
Gieger, Christian ;
Geistlinger, Ludwig ;
Altmaier, Elisabeth ;
de Angelis, Martin Hrabe ;
Kronenberg, Florian ;
Meitinger, Thomas ;
Mewes, Hans-Werner ;
Wichmann, H. -Erich ;
Weinberger, Klaus M. ;
Adamski, Jerzy ;
Illig, Thomas ;
Suhre, Karsten .
PLOS GENETICS, 2008, 4 (11)
[8]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[9]  
Griffiths W.J., 2008, METABOLOMICS METABON
[10]   A genome-wide perspective of genetic variation in human metabolism [J].
Illig, Thomas ;
Gieger, Christian ;
Zhai, Guangju ;
Roemisch-Margl, Werner ;
Wang-Sattler, Rui ;
Prehn, Cornelia ;
Altmaier, Elisabeth ;
Kastenmueller, Gabi ;
Kato, Bernet S. ;
Mewes, Hans-Werner ;
Meitinger, Thomas ;
de Angelis, Martin Hrabe ;
Kronenberg, Florian ;
Soranzo, Nicole ;
Wichmann, H-Erich ;
Spector, Tim D. ;
Adamski, Jerzy ;
Suhre, Karsten .
NATURE GENETICS, 2010, 42 (02) :137-U66